Default company panoramic image
Logo

Clarity Pharmaceuticals

Clarity adds value to therapeutics through the development of companion diagnostics using targeted molecular imaging

  • Stage Product In Development
  • Industry Biotechnology
  • Location Sydney, NSW, Australia
  • Currency AUD
  • Founded April 2010
  • Employees 4
  • Website claritypharmaceuticals.com

Company Summary

Clarity has imaging technology that allows drugs (antibodies & peptides) to be seen in the body. The technology adds significant value to drugs that are in development by generating data that was previously unattainable; defining mechanism of action; & choosing patients that will respond to the therapy. Clarity offers this as a service to domestic & international biotech & pharma companies & uses it to extract value from in-licensed therapeutics.

Team

  • Default avatar
    Dr Matthew Harris
    MANAGING DIRECTOR

    Matt Harris has specific experience in early stage biotechnology development having been CEO of Avastra, Glycan Biosciences, CIMTECH, Gateway Capital and TM Ventures, and a Director of 4 start-ups. He has experience in the radiopharmaceutical industry, a PhD in cancer research and an MBA. He is supported by business development experts, scientific leaders and high net worth investors.

  • Default avatar
    Tony Romagnino
    BUSINESS DEVELOPMENT MANAGER

    As the former General Manager of Technology Commercialisation at NewSouth Innovations (NSi), Tony's team quadrupled the licensing research and commercial income at UNSW & closed one of the single largest licensing deals in the history of UNSW in nuclear medicine. Tony has managed eight spin out companies and was the UNSW/NSi Investment Manager at Uniseed, a university-based venture capital firm managing $60m in pre-seed investments.

  • Default avatar
    Dr Alan Taylor
    EXECUTIVE CHAIRMAN

    Alan has a background in both investment banking and medical science and brings a wealth of experience to Clarity. He has ten years investment banking experience, and was until very recently an Executive Director and shareholder of Inteq Limited, a boutique Australian investment bank, where he remains on the Board of Directors. At Inteq, Alan was involved in some of Australia’s largest life sciences listings on the Australian Securities Exchange.

  • Default avatar
    Amos Hedt
    Head of Clinical and Contract Services

    Amos has extensive experience managing clinical projects. His most recent role as Senior Director of Clinical Operations at Patrys Ltd has given him commercial experience & insight into what biotech companies require for services like Clarity's. Amos was previously a Clinical Trial Manager at CSL, giving him further insight into the clinical trial process. He has had extensive experience in business development and building & pitching proposals.

Advisors

  • Default avatar
    Moray & Agnew
    Lawyer
    Unconfirmed
    Default avatar
    Lawler Partners
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Hunter Angel Trust
    Unconfirmed
    Default avatar
    TM Ventures
    Unconfirmed
    Default avatar
    Seaspin Pty Ltd, HirstShabianHirst
    Unconfirmed